Press Releases

Dec 10, 2020

Sanofi to resume dosing in fitusiran clinical studies in the U.S.
Nov 18, 2020

Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia

Phase 3 trial initiated to evaluate rilzabrutinib, the potential first BTK inhibitor (Bruton’s tyrosine kinase inhibitor) for the treatment of immune thrombocytopenia
Nov 18, 2020

FDA grants priority review for avalglucosidase alfa, a potential new therapy for Pompe disease

The FDA decision date for avalglucosidase alfa, an investigational enzyme replacement therapy, is set for May 18, 2021
Nov 13, 2020

FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease

Complete Response Letter refers to deficiencies from a pre-license inspection of a third-party manufacturing facility
Nov 5, 2020

New clinical and health-related quality of life data in multiple myeloma and rare blood disorders to be presented at ASH 2020

Oncology: Results from an interim analysis of Sarclisa® (isatuximab-irfc) in patients with relapsed multiple myeloma, including an evaluation of depth of response, will be shared in an oral presentation

Show per page